Wir verwenden standardmäßig essenzielle Cookies (Anmeldung, deine gespeicherten Ziele/Stacks). Mit deiner Erlaubnis aktivieren wir außerdem datenschutzfreundliche Analytik (Vercel Web Analytics, anonyme Ladezeit-Metriken) und Fehler-Replay-Diagnostik (Sentry — DOM-Snapshots nur, wenn ein Fehler auftritt), damit wir Bugs schneller beheben können. Mehr über Cookies erfahren
Slu3.0
SLU-PP-332 – Forschung
Überwiegend Mechanismus / Beobachtung
5 begutachtete Studien
Was die Evidenz sagt
Überwiegend Mechanismus / Beobachtung
Die meisten Studien zu SLU-PP-332 sind mechanistisch oder beobachtend statt RCTs, die einen klinischen Effekt messen — betrachte die Ergebnisse als vorläufig.
Die meiste Evidenz stammt aus gemischt-qualitativen Studien, veröffentlicht 2023–2025.
Basierend auf 5 Studien
Konfidenz
Geringe Konfidenz
Nach Outcome
Endurance & exercise capacity (preclinical)Erhöhte Ausdauer und Fettoxidation bei Mäusen als pan-ERR-"Exercise-Mimetikum"; keinerlei Humandaten. · Nicht etabliert (keine Humandaten)
Zu wenige bewertete Studien2 Studien
Metabolic & fat oxidation (preclinical)
Zu wenige bewertete Studien1 Studie
Cardiac & heart failure (preclinical)
Zu wenige bewertete Studien1 Studie
Aging & healthspan (preclinical)
Zu wenige bewertete Studien1 Studie
Safety profile
Zu wenige bewertete Studien1 Studie
Aktives Forschungsgebiet
5 Studien in den letzten 5 Jahren
1Tierstudie2023
Einfach gesagt: An 8-week treatment with a pan-ERR agonist (SLU-PP-332) reversed the age-related increases in albuminuria, podocyte loss, mitochondrial dysfunction, and inflammatory cytokines in aged mice.
Wang XX, Myakala K, Libby AE, Krawczyk E, Panov J, Jones BA, et al. · Am J Pathol (2023)
Treated 21-month-old mice with the pan-ERR agonist SLU-PP-332 for 8 weeks
Reversed age-related albuminuria, podocyte loss, mitochondrial dysfunction, and inflammation — similar to lifelong caloric restriction
Acts via cGAS-STING and STAT3 signaling; ERR expression was lower in aging human and mouse kidneys
Einfach gesagt: Both SLU-PP-332 and SLU-PP-915 significantly improved ejection fraction, ameliorated fibrosis, and increased survival associated with pressure overload-induced heart failure.
Xu W, Billon C, Li H, Wilderman A, Qi L, Graves A, et al. · Circulation (2024)
Tested SLU-PP-332 and the sibling pan-ERR agonist SLU-PP-915 in a mouse pressure-overload heart-failure model
Both improved ejection fraction, reduced fibrosis, and increased survival without affecting cardiac hypertrophy
Mechanism via transcriptional activation of fatty-acid-metabolism and mitochondrial genes, increasing cardiac oxidative capacity and fatty-acid use in vivo and in vitro
Einfach gesagt: Pharmacological exercise mimetics may be effective in the treatment of obesity and metabolic syndrome; SLU-PP-332, an ERR agonist, alleviated metabolic syndrome in mice.
Billon C, Schoepke E, Avdagic A, Chatterjee A, Butler AA, Elgendy B, et al. · J Pharmacol Exp Ther (2024)
Direct follow-up testing SLU-PP-332 as a pharmacological exercise mimetic in a mouse metabolic-disease model
Enhanced fatty-acid/fat oxidation and alleviated features of diet-induced obesity and metabolic syndrome
Frames ERR agonism as a candidate approach for obesity and metabolic syndrome
Foundational paper introducing SLU-PP-332 — the first synthetic compound with meaningful ERRα agonist activity (ERRβ/γ agonists existed before; ERRα had been hard to drug)
In mice, the compound induced the same acute aerobic-exercise transcriptional program in skeletal muscle that physical exercise triggers, and the response was ERRα-dependent
Enhanced exercise capacity (running performance) — the central 'exercise mimetic' result
Einfach gesagt: Primary cultures of myoblasts from inactive women were treated with the ERRs agonist SLU-PP-332 to assess metabolic and expression changes associated with ERR activation.
Bonanni R, Falvino A, Matticari A, Rinaldi AM, D'Arcangelo G, Cifelli P, et al. · Front Physiol (2025)
Applied SLU-PP-332 to myoblasts cultured from muscle biopsies of physically inactive women — an ex-vivo human-cell pilot, NOT a human clinical trial
Inactive women's muscle showed reduced SIRT1, PGC-1α, ERRα, and FNDC5 (and elevated NOX4) versus active women
Probes the PGC-1α/ERRα 'exercise' axis the compound is proposed to activate, in human-derived cells